Honokiol Cancer Research Results

HNK, Honokiol: Click to Expand ⟱

Features:

Honokiol is a Lignan isolated from bark, seed cones and leaves of trees of Magnolia species. Honokiol was traditionally used for anxiety and stroke treatment, as well as the alleviation of flu symptoms.
-considered to have antioxidant properties
-low oral bioavailability and difficulty in intravenous administration
-the development of various formulations of honokiol, including microemulsion, liposomes, nanoparticles and micelle copolymers have successfully solved the problem of low water solubility.

Pathways:
-Inhibit NF-κB activation
-Downregulate STAT3 signalin
-Inhibiting the PI3K/Akt pathway,
-Inhibition of mTOR
-Influences various MAPK cascades—including ERK, JNK, and p38
-Inhibition of EGFR
-Inhibiting Notch pathway (CSCs)
-GPx4 inhibit
-Can induce ER stress in cancer cells, which contributes to the activation of unfolded protein response (UPR) pathways
-Disrupt the mitochondrial membrane potential in cancer cells.
-Reported to increase ROS production in cancer cells
-Can exhibit antioxidant properties in normal cells. - has some inhibitor activity but Not classified as HDAC inhibitor as weaker and may work more indirectly.
- is well-known in the research community for its role in activating SIRT3

-Note half-life 40–60 minutes
BioAv
Pathways:
- induce ROS production in cancer cells, and typically lowers ROS in normal cells
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, GRP78↑, Ca+2↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓ Prx
- Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, Pro-Inflammatory Cytokines : IL-1β↓, TNF-α↓, IL-6↓,
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, EMT↓, MMPs↓, MMP2↓, MMP9↓, VEGF↓, ROCK1↓, RhoA↓, NF-κB↓, CXCR4↓, ERK↓
- reactivate genes thereby inhibiting cancer cell growth : HDAC↓, EZH2↓, P53↑, HSP↓,
- cause Cell cycle arrest : TumCCA↑, cyclin D1↓, cyclin E↓, CDK2↓, CDK4↓, CDK6↓,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, ERK↓, EMT↓,
- inhibits glycolysis and ATP depletion : HIF-1α↓, cMyc↓, GLUT1↓, LDH↓, LDHA↓, HK2↓, PDKs↓, ECAR↓, OXPHOS↓, GRP78↑, GlucoseCon↓
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, EGFR↓,
- inhibits Cancer Stem Cells : CSC↓, CD133↓, β-catenin↓, sox2↓, nestin↓, OCT4↓,
- Others: PI3K↓, AKT↓, JAK↓, STAT↓, Wnt↓, β-catenin↓, AMPK, ERK↓, JNK, TrxR**, - Shown to modulate the nuclear translocation of SREBP-2 (related to cholesterol).
- Synergies: chemo-sensitization, chemoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Cognitive, Renoprotection, Hepatoprotective, CardioProtective,

- Selectivity: Cancer Cells vs Normal Cells

Rank	Pathway / Axis	Cancer Cells	Normal Cells	Label	Primary Interpretation	Notes
1	Mitochondrial integrity / intrinsic apoptosis	↓ ΔΨm; ↑ cytochrome-c release; ↑ caspases	↔ largely preserved	Driver	Mitochondria-directed cytotoxicity	Honokiol directly accumulates in mitochondria and initiates intrinsic apoptosis in cancer cells
2	Reactive oxygen species (ROS)	↑ ROS (secondary, stress-amplifying)	↔ buffered	Secondary	Mitochondrial stress amplification	ROS elevation follows mitochondrial perturbation rather than acting as the initiating trigger
3	STAT3 signaling	↓ STAT3 activation	↔ minimal	Driver	Loss of survival and stemness signaling	STAT3 suppression contributes to apoptosis, CSC targeting, and reduced proliferation
4	PI3K → AKT → mTOR axis	↓ AKT / ↓ mTOR	↔ adaptive suppression	Secondary	Growth and anabolic inhibition	AKT/mTOR inhibition reinforces mitochondrial and apoptotic stress
5	NF-κB signaling	↓ NF-κB activation	↓ inflammatory NF-κB tone	Secondary	Suppression of survival transcription	NF-κB inhibition contributes to chemosensitization and anti-inflammatory effects
6	Cell cycle regulation	↑ G0/G1 or G2/M arrest	↔ spared	Phenotypic	Cytostatic growth control	Cell-cycle arrest reflects upstream signaling disruption
7	Autophagy	↑ autophagy (context-dependent)	↑ adaptive autophagy	Adaptive	Stress response vs death cooperation	Autophagy may precede apoptosis or act as a transient survival response

Scientific Papers found: Click to Expand⟱

2895-

HNK,

Mitochondria-Targeted Honokiol Confers a Striking Inhibitory Effect on Lung Cancer via Inhibiting Complex I Activity

in-vitro,

Lung,

PC9

 0.26 μM

"highlight2" >eff↑, "highlight2" >TumCP↓, "highlight2" >mt-ROS↑, "highlight2" >Prx3↑, "highlight2" >mt-STAT3↓, "highlight2" >*toxicity∅, "highlight2" >selectivity↑, "highlight2" >ChemoSen↑,

960-

HNK,

Honokiol Inhibits HIF-1α-Mediated Glycolysis to Halt Breast Cancer Growth

vitro+vivo,

BC,

MCF-7

HNK (diluted in DMSO, 25 mg/kg/day

mice

vitro+vivo,

BC,

MDA-MB-231

0-40uM/24hr

"highlight2" >OCR↑, "highlight2" >ECAR↓, "highlight2" >GlucoseCon↓, "highlight2" >lactateProd↓, "highlight2" >ATP↓, "highlight2" >Glycolysis↓, "highlight2" >Hif1a↓, "highlight2" >GLUT1↓, "highlight2" >HK2↓, "highlight2" >PDK1↓, "highlight2" >Apoptosis↑, "highlight2" >LDHA↓,

2881-

HNK,

Honokiol Suppressed Pancreatic Cancer Progression via miR-101/Mcl-1 Axis

in-vitro,

PC,

PANC1

 50 µM

"highlight2" >tumCV↓, "highlight2" >Casp3↑, "highlight2" >Apoptosis↑, "highlight2" >TumCCA↑, "highlight2" >TumCI↓, "highlight2" >Mcl-1↓, "highlight2" >EMT↓,

2882-

HNK,

Honokiol Suppresses Perineural Invasion of Pancreatic Cancer by Inhibiting SMAD2/3 Signaling

in-vitro,

PC,

PANC1

"highlight2" >TumCI↓, "highlight2" >TumCMig↓, "highlight2" >p‑SMAD2↓, "highlight2" >p‑SMAD3↓, "highlight2" >EMT↓, "highlight2" >N-cadherin↓, "highlight2" >Vim↓, "highlight2" >E-cadherin↑, "highlight2" >Snail↓, "highlight2" >Slug↓, "highlight2" >Rho↓, "highlight2" >ROCK1↓,

2883-

HNK,

Honokiol targets mitochondria to halt cancer progression and metastasis

Review,

Var,

"highlight2" >ChemoSen↑, "highlight2" >BBB↓, "highlight2" >Ca+2↑, "highlight2" >Cyt‑c↑, "highlight2" >Casp3↑, "highlight2" >chemoPv↑, "highlight2" >OCR↓, "highlight2" >mitResp↓, "highlight2" >Apoptosis↑, "highlight2" >RadioS↑, "highlight2" >NF-kB↓, "highlight2" >Akt↓, "highlight2" >TNF-α↓, "highlight2" >PGE2↓, "highlight2" >VEGF↓, "highlight2" >NO↝, "highlight2" >COX2↓, "highlight2" >RAS↓, "highlight2" >EMT↓, "highlight2" >Snail↓, "highlight2" >N-cadherin↓, "highlight2" >β-catenin/ZEB1↓, "highlight2" >E-cadherin↑, "highlight2" >ER Stress↑, "highlight2" >p‑STAT3↓, "highlight2" >EGFR↓, "highlight2" >mTOR↓, "highlight2" >mt-ROS↑, "highlight2" >PI3K↓, "highlight2" >Wnt↓,

2884-

HNK,

Honokiol inhibits EMT-mediated motility and migration of human non-small cell lung cancer cells in vitro by targeting c-FLIP

in-vitro,

Lung,

A549

in-vitro,

Lung,

H460

"highlight2" >EMT↓, "highlight2" >cFLIP↓, "highlight2" >N-cadherin↓, "highlight2" >Snail↓, "highlight2" >p‑SMAD2↓, "highlight2" >p‑SMAD3↓, "highlight2" >IKKα↑, "highlight2" >TumCMig↓,

2885-

HNK,

Honokiol: a novel natural agent for cancer prevention and therapy

"highlight2" >NF-kB↓, "highlight2" >STAT3↓, "highlight2" >EGFR↓, "highlight2" >mTOR↓, "highlight2" >BioAv↝, "highlight2" >Inflam↓, "highlight2" >TumCP↓, "highlight2" >angioG↓, "highlight2" >TumCI↓, "highlight2" >TumMeta↓, "highlight2" >cSrc↓, "highlight2" >JAK1↓, "highlight2" >JAK2↓, "highlight2" >ERK↓, "highlight2" >Akt↓, "highlight2" >PTEN↑, "highlight2" >ChemoSen↑, "highlight2" >chemoP↑, "highlight2" >COX2↓, "highlight2" >PGE2↓, "highlight2" >TNF-α↓, "highlight2" >IL1β↓, "highlight2" >IL6↓, "highlight2" >Casp3↑, "highlight2" >Casp8↑, "highlight2" >Casp9↑, "highlight2" >cl‑PARP↑, "highlight2" >DNAdam↑, "highlight2" >Cyt‑c↑, "highlight2" >RadioS↑, "highlight2" >RAS↓, "highlight2" >BBB↑, "highlight2" >BioAv↓, "highlight2" >Half-Life↝, "highlight2" >Half-Life↝, "highlight2" >toxicity↓,

2886-

HNK,

Liposomal honokiol inhibits non-small cell lung cancer progression and enhances PD-1 blockade via suppressing M2 macrophages polarization

in-vitro,

Lung,

A549

in-vitro,

Lung,

H460

in-vivo,

NA,

 mouse Lewis lung cancer cell line (LL2

"highlight2" >eff↑, "highlight2" >BioAv↑, "highlight2" >eff↑, "highlight2" >PI3K↓, "highlight2" >Akt↓,

2887-

HNK,

Honokiol Restores Microglial Phagocytosis by Reversing Metabolic Reprogramming

in-vitro,

AD,

BV2

"highlight2" >*Glycolysis↑, "highlight2" >*ATP↑, "highlight2" >*ROS↓, "highlight2" >*MMP↑, "highlight2" >*OXPHOS↑, "highlight2" >*PPARα↑, "highlight2" >*PGC-1α↑,

2888-

HNK,

Honokiol mediated inhibition of PI3K/mTOR pathway: A potential strategy to overcome immunoresistance in glioma, breast and prostate carcinoma without impacting T cell function

in-vitro,

Var,

PC3

in-vitro,

BC,

BT549

"highlight2" >PI3K↓, "highlight2" >mTOR↓, "highlight2" >Inflam↓,

2889-

HNK,

doxoR,

Honokiol, an activator of Sirtuin-3 (SIRT3) preserves mitochondria and protects the heart from doxorubicin-induced cardiomyopathy in mice

in-vivo,

Nor,

mice

"highlight2" >*SIRT3↑, "highlight2" >chemoP↑, "highlight2" >*cardioP↑, "highlight2" >mtDam↑, "highlight2" >ROS↑, "highlight2" >*ROS↓, "highlight2" >*MMP↑,

2890-

HNK,

SIRT3 activation promotes enteric neurons survival and differentiation

"highlight2" >*SIRT3↑, "highlight2" >*antiOx↑, "highlight2" >*neuroP↑,

2891-

HNK,

Honokiol, an Active Compound of Magnolia Plant, Inhibits Growth, and Progression of Cancers of Different Organs

Review,

Var,

"highlight2" >AntiCan↑, "highlight2" >Inflam↓, "highlight2" >antiOx↑, "highlight2" >selectivity↑, "highlight2" >*toxicity↓, "highlight2" >cycD1/CCND1↓, "highlight2" >cycE/CCNE↓, "highlight2" >CDK2↓, "highlight2" >CDK4↓, "highlight2" >TumMeta↓, "highlight2" >NADPH↓, "highlight2" >MMP2↓, "highlight2" >MMP9↓, "highlight2" >p‑mTOR↓, "highlight2" >EGFR↓, "highlight2" >EMT↓, "highlight2" >SIRT1↑, "highlight2" >SIRT3↑, "highlight2" >EZH2↓, "highlight2" >Snail↓, "highlight2" >Vim↓, "highlight2" >N-cadherin↓, "highlight2" >E-cadherin↑, "highlight2" >COX2↓, "highlight2" >NF-kB↓, "highlight2" >*ROS↓, "highlight2" >Ca+2↑, "highlight2" >ROS↑,

2892-

HNK,

Honokiol Induces Apoptosis, G1 Arrest, and Autophagy in KRAS Mutant Lung Cancer Cells

in-vitro,

Lung,

A549

 30.42

in-vitro,

Lung,

H460

50.58

in-vitro,

Lung,

H385

59.38 ± 6.75 μM

in-vitro,

Nor,

BEAS-2B

"highlight2" >TumCCA↑, "highlight2" >Apoptosis↑, "highlight2" >SIRT3↑, "highlight2" >Hif1a↓, "highlight2" >selectivity↑, "highlight2" >p‑mTOR↓, "highlight2" >p70S6↓,

2893-

HNK,

doxoR,

Honokiol protects against doxorubicin cardiotoxicity via improving mitochondrial function in mouse hearts

in-vivo,

Nor,

rat

"highlight2" >*mitResp↑, "highlight2" >*PPARγ↑, "highlight2" >*cardioP↑, "highlight2" >*SIRT3↑, "highlight2" >*ROS↓, "highlight2" >*GSH↑, "highlight2" >*SOD2↑,

2894-

HNK,

Pharmacological features, health benefits and clinical implications of honokiol

Review,

Var,

Review,

AD,

"highlight2" >*BioAv↓, "highlight2" >*neuroP↑, "highlight2" >*BBB↑, "highlight2" >*ROS↓, "highlight2" >*Keap1↑, "highlight2" >*NRF2↑, "highlight2" >*Casp3↓, "highlight2" >*SIRT3↑, "highlight2" >*Rho↓, "highlight2" >*ERK↓, "highlight2" >*NF-kB↓, "highlight2" >angioG↓, "highlight2" >RAS↓, "highlight2" >PI3K↓, "highlight2" >Akt↓, "highlight2" >mTOR↓, "highlight2" >*memory↑, "highlight2" >*Aβ↓, "highlight2" >*PPARγ↑, "highlight2" >*PGC-1α↑, "highlight2" >NF-kB↓, "highlight2" >Hif1a↓, "highlight2" >VEGF↓, "highlight2" >HO-1↓, "highlight2" >FOXM1↓, "highlight2" >p27↑, "highlight2" >P21↑, "highlight2" >CDK2↓, "highlight2" >CDK4↓, "highlight2" >CDK6↓, "highlight2" >cycD1/CCND1↓, "highlight2" >Twist↓, "highlight2" >MMP2↓, "highlight2" >Rho↑, "highlight2" >ROCK1↑, "highlight2" >TumCMig↓, "highlight2" >cFLIP↓, "highlight2" >BMPs↑, "highlight2" >OCR↑, "highlight2" >ECAR↓, "highlight2" >*AntiAg↑, "highlight2" >*cardioP↑, "highlight2" >*antiOx↑, "highlight2" >*ROS↓, "highlight2" >P-gp↓,

2880-

HNK,

Honokiol inhibits breast cancer cell metastasis by blocking EMT through modulation of Snail/Slug protein translation

in-vitro,

BC,

MCF-7

in-vitro,

BC,

MDA-MB-231

in-vitro,

BC,

4T1

in-vivo,

NA,

50 mg/kg every day, intraperitoneal (i.p.), 6 times per week for 30 days

mouse

"highlight2" >tumCV↓, "highlight2" >E-cadherin↑, "highlight2" >Snail↓, "highlight2" >Slug↓, "highlight2" >Vim↓, "highlight2" >TumMeta↓, "highlight2" >p‑eIF2α↑,

2896-

HNK,

Honokiol inhibits hypoxia-inducible factor-1 pathway

in-vivo,

Colon,

CT26

subcutaneous murine colon carcinoma, CT26

"highlight2" >Hif1a↓, "highlight2" >RadioS↑,

2897-

HNK,

Honokiol Inhibits Proliferation, Invasion and Induces Apoptosis Through Targeting Lyn Kinase in Human Lung Adenocarcinoma Cells

in-vitro,

Lung,

PC9

0, 20, 40, 60, and 80 μM

41uM@48h

in-vitro,

Lung,

A549

52uM@48h

"highlight2" >TumCP↓, "highlight2" >Apoptosis↑, "highlight2" >EGFR↓, "highlight2" >PI3K↓, "highlight2" >Akt↓, "highlight2" >STAT3↓, "highlight2" >TumCI↓, "highlight2" >TNF-α↑, "highlight2" >NF-kB↓, "highlight2" >VEGF↓, "highlight2" >MMP9↓, "highlight2" >COX2↓,

2898-

HNK,

Honokiol Suppression of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Cell Biological Activity and Its Mechanism

in-vitro,

GC,

AGS

in-vitro,

GC,

NCI-N87

in-vitro,

BC,

MGC803

in-vitro,

GC,

SGC-7901

"highlight2" >TumCP↓, "highlight2" >Apoptosis↑, "highlight2" >TumCI↓, "highlight2" >TumCMig↓, "highlight2" >HER2/EBBR2↓, "highlight2" >TumCCA↑, "highlight2" >PI3K↓, "highlight2" >Akt↓, "highlight2" >MMP9↓, "highlight2" >P21↑,

2899-

HNK,

SIRT3 activator honokiol ameliorates surgery/anesthesia-induced cognitive decline in mice through anti-oxidative stress and anti-inflammatory in hippocampus

in-vivo,

Nor,

Adult C57BL/6 mice

"highlight2" >*memory↑, "highlight2" >*Inflam↓, "highlight2" >*ROS↓, "highlight2" >neuroP↑, "highlight2" >SIRT3↑, "highlight2" >ac‑SOD2↓,

2900-

HNK,

The Role and Therapeutic Perspectives of Sirtuin 3 in Cancer Metabolism Reprogramming, Metastasis, and Chemoresistance

Review,

Var,

"highlight2" >SIRT3↑, "highlight2" >Hif1a↓, "highlight2" >ChemoSen↑, "highlight2" >chemoP↑,

2901-

HNK,

doxoR,

Honokiol protects against doxorubicin cardiotoxicity via improving mitochondrial function in mouse hearts

in-vivo,

Nor,

mice

"highlight2" >*mitResp↑, "highlight2" >*PPARγ↑, "highlight2" >*Inflam↓, "highlight2" >*ROS↓, "highlight2" >*cardioP↑, "highlight2" >*SOD2↑, "highlight2" >*LDH↓,

2902-

HNK,

Rad,

Honokiol Mitigates Ionizing Radiation-Induced Injury by Maintaining the Redox Balance of the TrxR/Trx System

in-vitro,

Nor,

BEAS-2B

"highlight2" >*TrxR1↑, "highlight2" >*Trx↑, "highlight2" >*radioP↑, "highlight2" >*ROS↓,

4238-

HNK,

Neuropharmacological potential of honokiol and its derivatives from Chinese herb Magnolia species: understandings from therapeutic viewpoint

Review,

AD,

NA,

Park,

"highlight2" >*BDNF↑, "highlight2" >*hepatoP↑, "highlight2" >*ALAT↓, "highlight2" >*AST↓, "highlight2" >*TNF-α↓, "highlight2" >*SIRT3↑, "highlight2" >*Aβ↓, "highlight2" >*Apoptosis↓, "highlight2" >*ROS↓, "highlight2" >*MMP↑, "highlight2" >*Ca+2↓, "highlight2" >*Casp3↓, "highlight2" >*Ach↑, "highlight2" >*PPARγ↑, "highlight2" >*PGC-1α↑, "highlight2" >*motorD↑, "highlight2" >*TNF-α↓, "highlight2" >*IL1β↓,

4239-

HNK,

Honokiol reverses depressive-like behavior and decrease in brain BDNF levels induced by chronic corticosterone injections in mice

in-vivo,

NA,

Adult Swiss albino mice

"highlight2" >*Mood↑, "highlight2" >*BDNF↑,

4240-

HNK,

Honokiol Exerts Antidepressant Effects in Rats Exposed to Chronic Unpredictable Mild Stress by Regulating Brain Derived Neurotrophic Factor Level and Hypothalamus–Pituitary–Adrenal Axis Activity

in-vivo,

NA,

Rat

"highlight2" >*BDNF↑,

4241-

HNK,

Effects of Honokiol on Neurological Injury and Cognitive Function in Mice with Intracerebral Hemorrhage by Regulating BDNF-TrkB-CREB Signaling Pathway

in-vivo,

Stroke,

mice

"highlight2" >*Apoptosis↓, "highlight2" >*cognitive↑, "highlight2" >*BDNF↑, "highlight2" >*TrkB↑, "highlight2" >*CREB↑,

4522-

HNK,

MAG,

Honokiol Is More Potent than Magnolol in Reducing Head and Neck Cancer Cell Growth

in-vitro,

HNSCC,

FaDu

"highlight2" >AntiCan↑, "highlight2" >tumCV↓, "highlight2" >eff↑, "highlight2" >survivin↓, "highlight2" >RadioS↑,

4523-

HNK,

MAG,

BA,

Honokiol-Magnolol-Baicalin Possesses Synergistic Anticancer Potential and Enhances the Efficacy of Anti-PD-1 Immunotherapy in Colorectal Cancer by Triggering GSDME-Dependent Pyroptosis

in-vitro,

CRC,

HCT116

in-vitro,

CRC,

LoVo

in-vivo,

CRC,

HCT116

mice

"highlight2" >AntiCan↑, "highlight2" >eff↑, "highlight2" >TumCP↓, "highlight2" >TumCCA↓, "highlight2" >cycD1/CCND1↓, "highlight2" >Pyro↑, "highlight2" >Apoptosis↑, "highlight2" >cl‑GSDME↑, "highlight2" >Bcl-2↓, "highlight2" >Cyt‑c↑, "highlight2" >Casp9↑, "highlight2" >TumCG↓,

4659-

HNK,

Honokiol Eliminates Human Oral Cancer Stem-Like Cells Accompanied with Suppression of Wnt/β-Catenin Signaling and Apoptosis Induction

in-vitro,

Oral,

"highlight2" >cl‑Casp3↑, "highlight2" >survivin↓, "highlight2" >Bcl-2↓, "highlight2" >CD44↓, "highlight2" >Wnt↓, "highlight2" >β-catenin/ZEB1↑, "highlight2" >EMT↓, "highlight2" >Slug↓, "highlight2" >Snail↓, "highlight2" >CSCs↓, "highlight2" >Apoptosis↑,

4688-

HNK,

Honokiol Suppresses Renal Cancer Cells’ Metastasis via Dual-Blocking Epithelial-Mesenchymal Transition and Cancer Stem Cell Properties through Modulating miR-141/ZEB2 Signaling

vitro+vivo,

RCC,

A498

"highlight2" >CSCs↓, "highlight2" >EMT↓, "highlight2" >TumCG↓, "highlight2" >PI3K↓, "highlight2" >Akt↓, "highlight2" >mTOR↓, "highlight2" >p‑Akt↓, "highlight2" >PTEN↑, "highlight2" >Wnt↓, "highlight2" >β-catenin/ZEB1↓,

2082-

HNK,

Revealing the role of honokiol in human glioma cells by RNA-seq analysis

in-vitro,

GBM,

U87MG

36.27 μM

In U87-MG cells, the optimum concentration of honokiol was 20 µM, and the optimum time was 48 h

in-vitro,

GBM,

U251

59.53 μM

n U251-MG cells, the optimum concentration of honokiol was 40 µM, and the optimum time was 48 h

"highlight2" >AntiCan↑, "highlight2" >TumCP↑, "highlight2" >TumAuto↑, "highlight2" >Apoptosis↑, "highlight2" >*BioAv↑, "highlight2" >*neuroP↑, "highlight2" >*NF-kB↑, "highlight2" >MAPK↑, "highlight2" >GPx4↑, "highlight2" >Tf↑, "highlight2" >BAX↑, "highlight2" >Bcl-2↓, "highlight2" >antiOx↑, "highlight2" >Hif1a↓, "highlight2" >Ferroptosis↑,

1004-

HNK,

RAPA,

Honokiol downregulates PD-L1 expression and enhances antitumor effects of mTOR inhibitors in renal cancer cells

in-vitro,

RCC,

"highlight2" >Apoptosis↑, "highlight2" >TumCCA↑, "highlight2" >ROS↑, "highlight2" >PD-L1↓, "highlight2" >IFN-γ↓,

1021-

HNK,

Honokiol suppress the PD-L1 expression to improve anti-tumor immunity in lung cancer

in-vivo,

Lung,

"highlight2" >PD-L1↓, "highlight2" >T-Cell↑, "highlight2" >CD4+↑, "highlight2" >CD8+↑, "highlight2" >TumCG↓,

1087-

HNK,

Honokiol Inhibits Non-Small Cell Lung Cancer Cell Migration by Targeting PGE2-Mediated Activation of β-Catenin Signaling

in-vitro,

Lung,

A549

in-vitro,

Lung,

H1299

in-vitro,

Lung,

H460

in-vitro,

Lung,

H226

"highlight2" >TumCMig↓, "highlight2" >COX2↓, "highlight2" >PGE2↓, "highlight2" >NF-kB↓, "highlight2" >p65↓, "highlight2" >β-catenin/ZEB1↓, "highlight2" >MMP2↓, "highlight2" >MMP9↓,

1119-

HNK,

Honokiol inhibits epithelial—mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E‐cadherin axis

vitro+vivo,

BC,

"highlight2" >EMT↓, "highlight2" >MSCmark↓, "highlight2" >EM↑, "highlight2" >STAT3↓, "highlight2" >Zeb1↓, "highlight2" >E-cadherin↑,

1120-

HNK,

Honokiol suppresses renal cancer cells' metastasis via dual-blocking epithelial-mesenchymal transition and cancer stem cell properties through modulating miR-141/ZEB2 signaling

vitro+vivo,

RCC,

"highlight2" >EMT↓, "highlight2" >CSCs↓, "highlight2" >TumCG↓, "highlight2" >miR-141↑,

1153-

HNK,

Honokiol Eliminates Glioma/Glioblastoma Stem Cell-Like Cells via JAK-STAT3 Signaling and Inhibits Tumor Progression by Targeting Epidermal Growth Factor Receptor

in-vitro,

GBM,

U251

in-vitro,

GBM,

U87MG

in-vivo,

NA,

mice + zebrafish

"highlight2" >tumCV↓, "highlight2" >Apoptosis↑, "highlight2" >TumCMig↓, "highlight2" >TumCI↓, "highlight2" >Bcl-2↓, "highlight2" >EGFR↓, "highlight2" >CD133↓, "highlight2" >Nestin↓, "highlight2" >Akt↓, "highlight2" >ERK↓, "highlight2" >Casp3↑, "highlight2" >p‑STAT3↓, "highlight2" >TumCG↓,

"highlight2" >cl‑PARP↑,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 67

Pathway results for Effect on Normal Cells:

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:94  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

Honokiol Cancer Research Results

Pathway results for Effect on Normal Cells:

Redox & Oxidative Stress ⓘ

Mitochondria & Bioenergetics ⓘ

Core Metabolism/Glycolysis ⓘ

Cell Death ⓘ

Transcription & Epigenetics ⓘ

Proliferation, Differentiation & Cell State ⓘ

Migration ⓘ

Barriers & Transport ⓘ

Immune & Inflammatory Signaling ⓘ

Synaptic & Neurotransmission ⓘ

Protein Aggregation ⓘ

Drug Metabolism & Resistance ⓘ

Clinical Biomarkers ⓘ

Functional Outcomes ⓘ

Home Page